FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149071817> ?p ?o ?g. }

• W2149071817 endingPage "1029" @default.
• W2149071817 startingPage "1021" @default.
• W2149071817 abstract "Abstract Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies. Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy–Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test. Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score. Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL." @default.
• W2149071817 created "2016-06-24" @default.
• W2149071817 creator A5006496749 @default.
• W2149071817 creator A5011537800 @default.
• W2149071817 creator A5026103305 @default.
• W2149071817 creator A5039180386 @default.
• W2149071817 creator A5041306590 @default.
• W2149071817 creator A5046311492 @default.
• W2149071817 creator A5089590489 @default.
• W2149071817 date "2008-09-01" @default.
• W2149071817 modified "2023-10-17" @default.
• W2149071817 title "Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer" @default.
• W2149071817 cites W1965522233 @default.
• W2149071817 cites W1978716373 @default.
• W2149071817 cites W2006994284 @default.
• W2149071817 cites W2029245281 @default.
• W2149071817 cites W2061843303 @default.
• W2149071817 cites W2064956790 @default.
• W2149071817 cites W2077880074 @default.
• W2149071817 cites W2089524549 @default.
• W2149071817 cites W2156575195 @default.
• W2149071817 cites W2157769714 @default.
• W2149071817 cites W2274948752 @default.
• W2149071817 cites W2314927739 @default.
• W2149071817 cites W2330814896 @default.
• W2149071817 cites W343111676 @default.
• W2149071817 doi "https://doi.org/10.1634/theoncologist.2008-0003" @default.
• W2149071817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18776057" @default.
• W2149071817 hasPublicationYear "2008" @default.
• W2149071817 type Work @default.
• W2149071817 sameAs 2149071817 @default.
• W2149071817 citedByCount "37" @default.
• W2149071817 countsByYear W21490718172012 @default.
• W2149071817 countsByYear W21490718172013 @default.
• W2149071817 countsByYear W21490718172014 @default.
• W2149071817 countsByYear W21490718172015 @default.
• W2149071817 countsByYear W21490718172016 @default.
• W2149071817 countsByYear W21490718172017 @default.
• W2149071817 countsByYear W21490718172018 @default.
• W2149071817 countsByYear W21490718172019 @default.
• W2149071817 countsByYear W21490718172020 @default.
• W2149071817 countsByYear W21490718172021 @default.
• W2149071817 countsByYear W21490718172022 @default.
• W2149071817 countsByYear W21490718172023 @default.
• W2149071817 crossrefType "journal-article" @default.
• W2149071817 hasAuthorship W2149071817A5006496749 @default.
• W2149071817 hasAuthorship W2149071817A5011537800 @default.
• W2149071817 hasAuthorship W2149071817A5026103305 @default.
• W2149071817 hasAuthorship W2149071817A5039180386 @default.
• W2149071817 hasAuthorship W2149071817A5041306590 @default.
• W2149071817 hasAuthorship W2149071817A5046311492 @default.
• W2149071817 hasAuthorship W2149071817A5089590489 @default.
• W2149071817 hasBestOaLocation W21490718171 @default.
• W2149071817 hasConcept C121608353 @default.
• W2149071817 hasConcept C126322002 @default.
• W2149071817 hasConcept C141071460 @default.
• W2149071817 hasConcept C142724271 @default.
• W2149071817 hasConcept C143998085 @default.
• W2149071817 hasConcept C159110408 @default.
• W2149071817 hasConcept C168563851 @default.
• W2149071817 hasConcept C203092338 @default.
• W2149071817 hasConcept C204787440 @default.
• W2149071817 hasConcept C27081682 @default.
• W2149071817 hasConcept C2776694085 @default.
• W2149071817 hasConcept C2777802072 @default.
• W2149071817 hasConcept C2779951463 @default.
• W2149071817 hasConcept C2780259306 @default.
• W2149071817 hasConcept C2780456651 @default.
• W2149071817 hasConcept C2781413609 @default.
• W2149071817 hasConcept C526805850 @default.
• W2149071817 hasConcept C71924100 @default.
• W2149071817 hasConceptScore W2149071817C121608353 @default.
• W2149071817 hasConceptScore W2149071817C126322002 @default.
• W2149071817 hasConceptScore W2149071817C141071460 @default.
• W2149071817 hasConceptScore W2149071817C142724271 @default.
• W2149071817 hasConceptScore W2149071817C143998085 @default.
• W2149071817 hasConceptScore W2149071817C159110408 @default.
• W2149071817 hasConceptScore W2149071817C168563851 @default.
• W2149071817 hasConceptScore W2149071817C203092338 @default.
• W2149071817 hasConceptScore W2149071817C204787440 @default.
• W2149071817 hasConceptScore W2149071817C27081682 @default.
• W2149071817 hasConceptScore W2149071817C2776694085 @default.
• W2149071817 hasConceptScore W2149071817C2777802072 @default.
• W2149071817 hasConceptScore W2149071817C2779951463 @default.
• W2149071817 hasConceptScore W2149071817C2780259306 @default.
• W2149071817 hasConceptScore W2149071817C2780456651 @default.
• W2149071817 hasConceptScore W2149071817C2781413609 @default.
• W2149071817 hasConceptScore W2149071817C526805850 @default.
• W2149071817 hasConceptScore W2149071817C71924100 @default.
• W2149071817 hasIssue "9" @default.
• W2149071817 hasLocation W21490718171 @default.
• W2149071817 hasLocation W21490718172 @default.
• W2149071817 hasOpenAccess W2149071817 @default.
• W2149071817 hasPrimaryLocation W21490718171 @default.
• W2149071817 hasRelatedWork W1978884813 @default.
• W2149071817 hasRelatedWork W2006824814 @default.
• W2149071817 hasRelatedWork W2037400652 @default.
• W2149071817 hasRelatedWork W2063164866 @default.

• next